Outcomes for people admitted to Australian and New Zealand intensive care units with primary, exacerbating, or incidental SARS-CoV-2 infections, 2022-23: a retrospective analysis of ANZICS data.
Journal
The Medical journal of Australia
ISSN: 1326-5377
Titre abrégé: Med J Aust
Pays: Australia
ID NLM: 0400714
Informations de publication
Date de publication:
17 Jul 2024
17 Jul 2024
Historique:
received:
17
03
2023
accepted:
15
01
2024
medline:
18
7
2024
pubmed:
18
7
2024
entrez:
17
7
2024
Statut:
aheadofprint
Résumé
To compare in-hospital mortality and intensive care unit (ICU) length of stay for people admitted to Australian and New Zealand ICUs during 2022-23 with coronavirus disease 2019 (COVID-19) pneumonitis, incidental or exacerbating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, or without SAR-CoV-2 infections. Retrospective cohort study; analysis of Australian and New Zealand Intensive Care Society (ANZICS) Adult Patient Database data. Adults (16 years or older) admitted to participating ICUs in Australia or New Zealand, 1 January 2022 - 30 June 2023. The primary outcome was in-hospital mortality, the secondary outcome ICU length of stay, each by SARS-CoV-2 infection attribution classification: primary COVID-19; exacerbating SARS-CoV-2 infection (SARS-CoV-2 infection was a contributing factor to the primary cause of ICU admission); incidental SARS-CoV-2 infections (SARS-CoV-2 infection detected during ICU admission but did not contribute to admission diagnosis); no SARS-CoV-2 infection. A total of 207 684 adults were admitted to 195 Australian and New Zealand ICUs during 2022-23; 2674 people (1.3%) had incidental SARS-CoV-2 infections, 4923 (2.4%) exacerbating infections, and 3620 (1.7%) primary COVID-19. Unadjusted in-hospital mortality for people with incidental SARS-CoV-2 infections (288 deaths, 10.8%) was lower than for those with exacerbating infections (928 deaths, 18.8%) or primary COVID-19 (830 deaths, 22.9%), but higher than for patients without SARS-CoV-2 infections (15 486 deaths, 7.9%). After adjusting for illness severity, frailty, geographic region, and type of hospital, mortality was higher for patients with incidental SARS-CoV-2 infections (adjusted odds ratio [aOR], 1.28; 95% confidence interval [CI], 1.10-1.50), exacerbating infections (aOR, 1.35; 95% CI, 1.22-1.48), or primary COVID-19 (aOR, 2.54; 95% CI, 2.30-2.81) than for patients without SARS-CoV-2 infections. After adjusting for diagnosis and illness severity, ICU stays were longer for people with incidental (mean difference, 3.3 hours; 95% CI, 2.4-4.2 hours) or exacerbating infections (0.8 hours; 95% CI, 0.2-1.5 hours) than for those without SARS-CoV-2 infections. Risk-adjusted in-hospital mortality and ICU length of stay are higher for people admitted to intensive care who have concomitant SARS-CoV-2 infections than for people who do not.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Medical Journal of Australia published by John Wiley & Sons Australia, Ltd on behalf of AMPCo Pty Ltd.
Références
World Health Organization. Coronavirus disease (COVID‐19) pandemic. Updated 2024. https://www.who.int/emergencies/diseases/novel‐coronavirus‐2019 (viewed Feb 2024).
Hodgson CL, Higgins AM, Bailey MJ, et al; COVID‐Recovery Study Investigators and the ANZICS Clinical Trials Group. Comparison of 6‐month outcomes of survivors of COVID‐19 versus non‐COVID‐19 critical illness. Am J Respir Crit Care Med 2022; 205: 1159‐1168.
Lim ZJ, Subramaniam A, Ponnapa Reddy M, et al. Case fatality rates for patients with COVID‐19 requiring invasive mechanical ventilation: a meta‐analysis. Am J Respir Crit Care Med 2021; 203: 54‐66.
Burrell AJ, Pellegrini B, Salimi F, et al. Outcomes for patients with COVID‐19 admitted to Australian intensive care units during the first four months of the pandemic. Med J Aus 2021; 214: 23‐30. https://www.mja.com.au/journal/2021/214/1/outcomes‐patients‐covid‐19‐admitted‐australian‐intensive‐care‐units‐during‐first
Saad M, Kennedy KF, Imran H, et al. Association between COVID‐19 diagnosis and in‐hospital mortality in patients hospitalized with ST‐segment elevation myocardial infarction. JAMA 2021; 326: 1940‐1952.
COVIDSurg Collaborative. Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS‐CoV‐2 infection: an international cohort study. Lancet 2020; 396: 27‐38.
WHO Rapid Evidence Appraisal for COVID‐19 Therapies (REACT) Working Group; Sterne JAC, Murthy S, Diaz JV, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID‐19: a meta‐analysis. JAMA 2020; 324: 1330‐1341.
REMAP‐CAP Investigators; Gordon AC, Mouncey PR, Al‐Beidh F, et al. Interleukin‐6 receptor antagonists in critically ill patients with COVID‐19. N Engl J Med 2020; 384: 1491‐1502.
Beigel JH, Tomashek KM, Dodd LE, et al; ACTT‐1 Study Group Members. Remdesivir for the treatment of COVID‐19: final report. N Engl J Med 2021; 383: 1813‐1826.
Voysey M, Clemens SAC, Madhi SA, et al; Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV‐19 vaccine (AZD1222) against SARS‐CoV‐2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021; 397: 99‐111.
Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of the Pfizer‐BioNTech and Oxford‐AstraZeneca vaccines on COVID‐19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case–control study. BMJ 2021; 373: n1088.
Bálint G, Vörös‐Horváth B, Széchenyi A. Omicron: increased transmissibility and decreased pathogenicity. Signal Transduct Target Ther 2022; 7: 151.
Iacobucci G. Covid‐19: unravelling the conundrum of omicron and deaths. BMJ 2022; 376: o254.
COVID‐19 National Incident Room Surveillance Team. COVID‐19 Australia: epidemiology report 56. Reporting period ending 5 December 2021. Communicable Diseases Intelligence; 20 Dec 2021. https://www1.health.gov.au/internet/main/publishing.nsf/Content/novel_coronavirus_2019_ncov_weekly_epidemiology_reports_australia_2020.backup‐25‐05‐2023 (viewed Jan 2024).
Australian Department of Health and Aged Care. A national COVID‐19 health management plan for 2023. 13 Dec 2022. https://www.health.gov.au/resources/publications/national‐covid‐19‐health‐management‐plan‐for‐2023?language=en (viewed Feb 2023).
Hall V, Foulkes S, Insalata F, SIREN Study Group. Protection against SARS‐CoV‐2 after COVID‐19 vaccination and previous infection. N Engl J Med 2022; 386: 1207‐1220.
Zar HJ, MacGinty R, Workman L, et al. Natural and hybrid immunity following four COVID‐19 waves: a prospective cohort study of mothers in South Africa. EClinicalMedicine 2022; 53: 101655.
COVID‐19 Epidemiology and Surveillance Team. COVID‐19 Australia: Epidemiology report 68. Reporting period ending 20 November 2022. Communicable Diseases intelligence; 19 Dec 2022. https://www1.health.gov.au/internet/main/publishing.nsf/Content/novel_coronavirus_2019_ncov_weekly_epidemiology_reports_australia_2020.backup‐25‐05‐2023 (viewed Jan 2024).
Paul E, Bailey M, Pilcher D. Risk prediction of hospital mortality for adult patients admitted to Australian and New Zealand intensive care units: development and validation of the Australian and New Zealand risk of death model. J Crit Care 2013; 28: 935‐941.
Rockwood K, Song X, MacKnight C, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ 2005; 173: 489‐495.
Straney LD, Udy AA, Burrell A, et al. Modelling risk‐adjusted variation in length of stay among Australian and New Zealand ICUs. PLoS One 2017; 12: e0176570.
Australian Bureau of Statistics. Australian Statistical Geography Standard (ASGS), volume 5: remoteness structure, July 2016 (1270.0.55.005). 16 Mar 2018. https://www.abs.gov.au/ausstats/abs@.nsf/7d12b0f6763c78caca257061001cc588/197264d1f636feb7ca258251000c8cca!OpenDocument (viewed Apr 2023).
Harris JE. Population‐based model of the fraction of incidental COVID‐19 hospitalizations during the Omicron BA.1 wave in the United States. COVID 2023; 3: 728‐743.
Voor In ‘t Holt AF, Haanappel CP, Rahamat‐Langendoen J, et al. Admissions to a large tertiary care hospital and omicron BA.1 and BA.2 SARS‐CoV‐2 polymerase chain reaction positivity: primary, contributing, or incidental COVID‐19. Int J Infect Dis 2022; 122: 665‐668.
COVIDSurg Collaborative. Elective surgery cancellations due to the COVID‐19 pandemic: global predictive modelling to inform surgical recovery plans. Br J Surg 2020; 107: 1440‐1449.
Wang J, Tong Y, Li D, Li Y. The impact of age difference on the efficacy and safety of COVID‐19 vaccines: a systematic review and meta‐analysis. Front Immunol 2021; 12: 758294.